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Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients
with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA
resistance and to develop a prediction model for the risk stratification in these patients.
Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes
undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses.
Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical
parameters, routine laboratory and specific biomarkers.
Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF,
use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard
to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels
were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP
levels as well as lower Osteocalcin levels were predictors of ESA resistance.
Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in
diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve
the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients
according to the risk of ESA resistance, which may help to assign appropriate treatment strategies.
Clinical trial registration: The study was registered at the German medical authority (BfArM; registration number
401 3206). The sponsor protocol ID and clinical trial unique identified number was CT-981-423-239. The results of
the study are published and available at http://www.ncbi.nlm.nih.gov/pubmed/16034009.Background
Despite advances in renal replacement therapy, mortality
of hemodialysis (HD) patients is still excessive [1]. Diabetes
mellitus is the leading cause of kidney disease. Almost half
of US dialysis patients developed end-stage renal disease
due to diabetes mellitus. Compared to non-diabetic dialysis
patients, diabetic dialysis patients show strikingly higher
mortality rates which is reflected by a five year survival of
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reproduction in any medium, provided the orAnemia is one of the major problems contributing to
the high comorbidity and poor outcome of diabetic
dialysis patients. Anemia treatment in chronic kidney
disease (CKD) patients has changed dramatically since
the implementation of Erythropoietin Stimulating Agents
(ESAs) into clinical practice in 1989. This has reduced the
need for blood transfusions, improving quality of life for
the patients [3]. ESA resistance has been defined by
the European Renal Association-European Dialysis and
Transplant Association (ERA-EDTA) as being present
when patients do not achieve the recommended
hemoglobin (Hb) target level (11–12 g/dl), despite a
treatment with ESAs over several months [4]. According
to this arbitrary definition, more than 90–95% of HD
patients treated with an ESA respond to the therapy withral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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5–10% do not adequately respond to the therapy. Of
note, resistance to ESAs has consistently been shown to be
associated with an increased risk of death and cardiovascu-
lar events in CKD patients [6-8]. In the recent TREAT trial,
diabetic patients with CKD were at highest risk of mortality
when they had a poor response to the initial two doses of
darbepoietin alfa [6]. Besides, ESA therapy is expensive and
leads to enormous costs for the Health Care Systems [9].
Therefore, strategies to reduce ESA resistance and to avoid
unnecessary ESA usage are required. In clinical practice,
tools to identify patients who most likely will benefit from
ESA therapy would be highly useful.
Several factors have been described to promote ESA
resistance in HD patients [7,10-13]. By now, inflammation,
malnutrition, secondary hyperparathyroidism (sHPT),
lower hemoglobin A1C (HbA1c), deplete iron stores and
vitamin D deficiency have been found to be associated
with ESA resistance. However, the combination of known
risk factors enabling to stratify patients into responders
and non-responders has not been investigated so far.
Hence, we developed a model predicting ESA resistance
in HD patients utilizing data of the prospective German
Diabetes and Dialysis Study (4D - Die Deutsche Diabetes
Dialyse-Studie) [14].
Methods
Design of the 4D study
The 4D study design, main outcome findings, and baseline
data have been described previously [14]. In short, the 4D
study was a prospective randomized controlled trial
recruiting 1255 hemodialysis patients with type 2 diabetes
mellitus, aged 18–80 years, from 178 German dialysis
centres. Eligible patients were randomly assigned to receive
either atorvastatin 20 mg daily or matching placebo. The
mean length of follow-up was 4.0 years. The primary end
point of the 4D study was defined as a composite of death
from cardiac causes, stroke and myocardial infarction. All
events were reviewed and adjudicated by a critical end
point committee blinded to treatment allocation [14].
The study adhered to the International Conference on
Harmonisation guidelines for Good Clinical Practice
and was conducted in accordance with the Declaration
of Helsinki. The protocol was approved by the ethics
committee at the University of Würzburg.
All participants provided written informed consent.
Data collection
Information on demographic characteristics such as age
and smoking status were obtained through patient inter-
views. Comorbidities including the presence of coronary
artery disease (CAD) and congestive heart failure (CHF),
as well as the duration of diabetes mellitus and dialysis
treatment, were reported by the patients’ nephrologists.Blood pressure was measured in a sitting position. Body
mass index (BMI) was calculated as weight (kilogram)
divided by height (metre squared).
ESA resistance
In the present study we calculated the ESA Resistance
Index (ERI), defined as the weekly weight-adjusted ESA
dose (U/kg/week) divided by hemoglobin level (g/dl). By
means of the ERI values (baseline data), patients were
divided into quartiles. The cut-off values were Quartile
1 < 4.19, Quartile 2 (4.20 – 6.64), Quartile 3 (6.65 – 10.11)
and Quartile 4 > 10.11, respectively. Patients in the upper
quartile were defined as ESA resistant. The ERI index
was calculated population-based in a cross-sectional
fashion at baseline.
Statistical analyses
Continuous variables were expressed as mean with
standard deviation (SD), and categorical variables were
expressed as percentages. We investigated potential
predictors of ESA resistance. Firstly, based on previous
knowledge from the literature and clinical relevance,
we evaluated demographic and clinical characteristics
(age, sex, body mass index, smoking status, systolic and
diastolic blood pressure, dialysis vintage, duration of
diabetes mellitus), comorbidities (CAD, CHF, peripheral
vascular disease), and the use of concomitant medication
(ACE-inhibitors, beta-blockers, diuretics).
Secondly, we investigated potential predictors from base-
line routine laboratory assessments including hemoglobin,
albumin, calcium, phosphate, potassium, urea, HbA1c,
alkaline phosphatase, iron and lipid status. Finally, specific
non-routinely used biomarkers were additionally evaluated
including N-terminal-pro-B-type-natriuretic peptide
(NT-pro-BNP), C-reactive protein, parathyroid hormone
(PTH), adiponectin, vitamin D (25(OH)D), troponin T,
osteocalcin, ADMA, osteoprotegerin and fetuin.
Variables were log transformed if necessary. We
performed univariate logistic regression analyses to assess
the association of clinical and laboratory markers with the
binary outcome of ESA resistance (yes/no). Odds ratios
(OR) and 95% confidence intervals were calculated.
Furthermore, we performed multivariate logistic re-
gression analyses to construct a prediction model for
ESA resistance. Predictors with a p-value < 0.1 in univariate
analyses were selected for inclusion in the multivariate
model. Backward selection procedures were applied in the
multivariate analyses. The construction of the prediction
model was performed in several steps. First, we established
a prediction model based on the clinical parameters
described above (model 1) and investigated whether the
addition of routine laboratory markers measured at baseline
(model 2) and specific biomarkers (model 3) further
improved risk stratification for ESA resistance. Prognostic
Table 1 Baseline patient characteristics, study population n = 1015
Characteristic n All Non epo-resistant Epo-resistant
Age years 1015 66 (8) 65 (8) 67 (8)
Gender % men 1015 53.9 55 41
Systolic BP mmHg 1015 145 (22) 146 (23) 147 (23)
Diastolic BP mmHg 1015 76 (11) 76 (11) 75 (11)
BMI kg/m2 1015 27.5 (4.8) 27.6 (4.8) 26.9 (5.0)
Duration of diabetes years 953 18.1 (8.8) 17.6 (8.7) 18.5 (8.7)
Time on dialysis months 1015 8.2 (6.9) 8.6 (7.0) 7.0 (6.5)
History of
CAD % 1015 28,50 28,50 28,50
CHF % 1015 35.4 32.2 41.9
PVD % 1015 44.6 43.8 46.6
Smoker or ex-smoker % 1015 40.4 40.8 34.4
use of ACE-inhibitors % 1015 48 48 54
heart rate bpm 988 79 (15) 78 (15) 81 (17)
Laboratory parameters 253 25 0 100
ERI-Index > 10.1 (%)*
LDL cholesterol mg/dl 1015 126 (30) 126 (31) 121 (27)
AP U/I 1015 123 (63)
HDL cholesterol mg/dl 1015 36 (13) 36 (13) 37 (15)
Triglycerides mg/dl 1015 264 (167) 269 (173) 260 (172)
Hemoglobin g/dl 1015 10.9 (1.3) 11.0 (1.2) 10.3 (1.5)
Albumin g/dl 1015 3.8 (0.3) 3.8 (0.3) 3.7 (0.3)
C-reactive protein mg/l 1009 5.8 (2.3-12.4) 9.9 (15.8) 14.7 (20.8)
Calcium mmol/l 1015 2.3 (0.2) 2.3 (0.2) 2.3 (0.2)
Phosphate mg/dl 1015 6.1 (1.6) 6.1 (1.6) 6.2 (1.6)
HbA1c % 1015 6.7 (1.3) 6.7 (1.2) 6.6 (1.3)
urea mg/dl 1015 143 (36) 144 (36) 137 (35)
potassium mmol/l 1015 5.2 (0.9) 5.2 (0.8) 5.4 (1.0)
ferritin μg/L 1015 487 (426) 520 (436) 442 (405)
iron saturation % 1015 22.2 (11.3) 23.3 (11.5) 17.9 (8.7)
NT-pro-BNP pg/ml 1009 3361 (1433–9271) 7885 (14153) 9609 (14105)
Troponin T ng/ml 1009 0.09 (0.13) 0.08 (0.11) 0.11 (1.17)
ADMA umol/l 1007 0.87 (0.16) 0.86 (0.15) 0.90 (0.16)
PTH pg/mL 1008 102 (119) 101 (117) 91 (127)
25(OH)Vitamin D ng/mL 1015 17.9 (9.8) 18.2 (10.1) 16.8 (8.8)
Osteocalcin ug/l 1008 107 (102) 109 (100) 101 (100)
Values are presented as mean ± SD or percentages.
Abbreviations: CAD = coronary artery disease; CHF = congestive heart failure, PVD = peripheral vascular disease.
BMI = body-mass index, LDL = low-density lipoprotein, HDL = high-density lipoprotein.
HbA1c = glycosylated hamoglobin, NT-pro-BNP = N-terminal pro b-type natriuretic peptide.
* ESA Resistance Index.
Cut-off values: Q1 < 4.19; Q2 (4,20-6.64); Q3 (6.65 – 10.11); Q4 > 10.11.
Patients in the upper ERI quartile were defined as ESA resistant.
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Table 2 Determinants for ESA resistance (Q4 ERI > 10.1):
univariate analyses
Characteristic OR 95% CI
(lower and upper limit)
P-value
Age years 1,02 1,00 1,04 0,05
Male sex 1,76 1,32 2,35 <0,001
Time on HD months 0,96 0,94 0,99 0,002
Smoker or ex-smoker 0,76 0,57 1,02 0,07
BMI kg/m2 0,97 0,94 1,00 0,06
Heart Rate bpm 1,01 1,00 1,02 0,02
History of CHF % 1,52 1,14 2,04 0,01
Use of ACE-Inhibitors % 1,27 0,96 1,69 0,09
Laboratory values
Iron saturation % 0,94 0,93 0,96 <0,001
Ferritin ug/l 1,00 0,99 1,00 0,01
Albumin g/dl 0,22 0,14 0,36 <0,001
Urea mg/dl 0,99 0,99 1,00 0,01
Potassium mmol/l 1,24 1,05 1,46 0,01
Glucose mg/dl 1,00 1,00 1,01 0,03
LDL-C mg/dl 0,99 0,99 1,00 0,03
AP U/l 1,64 1,15 2,36 0,01
Biomarker
NT-pro-BNP pg/ml 1,21 1,08 1,35 0,00
PTH ng/l 0,86 0,75 0,99 0,04
CRP mg/l 1,24 1,10 1,39 0,00
Troponin T ng/ml 1,20 1,03 1,40 0,02
ADMA umol/l 4,45 1,81 10,98 0,00
25(OH) vitamin D ng/ml 0,75 0,55 1,02 0,07
Osteocalcin ug/l 0,85 0,71 1,01 0,06
Abbreviations:
ACEI = Angiotensin-Converting-Enzym Inhibitor; AP = alkaline phosphatase.
PTH = parathyroid-hormone; CRP = C-reactive protein.
ADMA = asymmetric dimethylarginin; 25(OH) vitamin D = cholecalciferol.
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performed using SPSS version 19.0.
Results
Patient characteristics at baseline
Altogether, 1255 patients were included into the 4D study,
of which 1015 had a measurement of the ESA-Index at
baseline. Table 1 shows the patients baseline characteristics.
Patients had a mean age of 66 years and 54% were
men. About one third of the patients had CAD or CHF.
More than half of the patients were non-smokers. All
patients had diabetes mellitus and underwent HD
treatment; the mean duration of diabetes was 18 years
and dialysis vintage 8 months. Patients with ESA resistance
had a significantly higher incidence of CVE by 33% as
compared to non-resistant patients during the median
follow-up of 4 years (HR 1.33, 95% CI 1.06-1.67, p = 0.013).
Mortality was even significantly increased by 44% and
highest with a 77% increase in the first year of follow-up
(HR 1.77, 95% CI 1.23-2.54, p = 0.002).
Predictors of ESA resistance from clinical parameters
We first analysed the role of clinical parameters for ESA
resistance. This was done as information on patients
demographic characteristics is easy accessible in the
daily clinic routine and free of additional costs. In the
study population (n = 1015), univariate analyses revealed
that older age, male sex, previous or current smoking
and a shorter dialysis vintage were associated with
ESA resistance (Table 2). Furthermore, a lower BMI,
higher heart rate, the presence of CHF and the use of
ACE-inhibitors were associated with ESA resistance
(all p-value <0.1). These parameters were selected for
inclusion in the multivariate model. After the application
of backward selection procedures, male sex, BMI, dia-
lysis vintage, heart rate, CHF and use of ACE inhibitors
remained in the final model of clinical parameters
(model 1) to predict ESA resistance (Table 3). On the
other hand, no associations were found between ESA
resistance and blood pressure, hypertension (yes/no),
PVD, arrhythmia, ultrafiltration volume, polyneuropathy,
retinopathy or the duration of hemodialysis treatment
per week.
Predictors of ESA resistance from routine laboratory
assessments
Multivariate analysis for clinical parameters + routine
laboratory
In the next step, we investigated routinely used laboratory
variables. The univariate analyses revealed that lower iron
saturation, ferritin, albumin, LDL cholesterol and urea
concentrations, as well as higher potassium, glucose and
alkaline phosphatase concentrations were associated with
ESA resistance (Table 2). Again, these parameters wereselected for inclusion in the multivariate model. After the
application of backward selection procedures, albumin,
urea, iron saturation, potassium and creatinine remained
the strongest laboratory parameters to predict ESA
resistance (Table 3). Concentrations of calcium, phosphate,
HbA1c, total and HDL-cholesterol, triglycerides, and
platelet count did not associate with ESA resistance in
the present analyses.
Predictors of ESA resistance from specific biomarker
assessments
Multivariate analysis for clinical parameters + routine
laboratory + specific biomarkers
Biomarkers that were significantly associated with ESA
resistance in univariate analyses included NT-pro-BNP,
PTH, high sensitive CRP, troponin T, ADMA, 25(OH)
vitamin D and osteocalcin (Table 2). When these were
Table 3 Predictors of ESA resistance
Predictors
Model 1 Model 2 Model 3
Clinical parameters Model 1 plus routine laboratory Model 2 plus specific biomarkers
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Sex (male) 1,72 1.27-2.32 <0.001 1,73 1.22-2.45 0.002 1,54 1.08-2.21 0.017
BMI (kg/m2) 0.97 0.94-1.00 0.048 0.96 0.93-0.996 0.03 0,96 0.92-0.99 0.02
dialysis vintage (mo) 0.97 0.95-0.99 0.011
CHF (%) 1,41 1.04-1.91 0.028 1,34 0.96-1.87 0.08 1,30 0.92-1.84 0.14
ACE-inhibitors (%) 1,32 0.98-1.78 0.071 1,33 0,96-1,84 0.09
heart rate (bpm) 1,01 1,00-1,02 0.052 1,01 1.00-1.02 0.029
albumin (g/dl) 0,29 0.17-0.52 <0.001 0,40 0.22-0.72 0.002
LDL-cholesterol (mg/dl) 0.996 0.99-1.001 0.125 0.995 0.989-1.001 0.098
creatinine (mg/dl) 1,08 0.99-1.17 0.087
urea (mg/dl) 0.996 0.991-1.001 0.10
iron saturation (%) 0,94 0.93-0.96 <0.001 0.95 0.93-0.97 <0.001
potassium (mmol/l) 1,21 0.99-1.47 0.062 1,34 1.09-1.64 0.005
CRP (mg/l) 1,18 1.02-1.38 0.028
Troponin T (ng/ml) 1,17 0.97-1.42 0.10
ADMA (umol/l) 5,24 1.75-15.70 0.003
Osteocalcin (ug/l) 0,82 0.66-1.01 0.064
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CRP and osteocalcin remained and slightly further im-
proved the risk stratification beyond clinical parameters
and routine laboratory (Table 3);
Discussion
In this post-hoc analysis from the 4D study we developed a
prediction model for ESA resistance with easily obtainable
clinical parameters, routinely collected laboratory variables
and non-routinely used biomarkers. Multivariate analysis
for clinical parameters revealed male sex, lower BMI and
dialysis vintage, a higher heart rate, the presence of
CHF and the use of ACEI as independent predictors
for ESA resistance. Among routine laboratory markers,
lower concentrations of albumin, iron saturation and
higher concentrations of potassium and creatinine
were independently associated with ESA resistance and
significantly improved risk stratification, when added
to the information derived from clinical parameters.
Specific biomarkers however did not further improve
the risk stratification for ESA resistance.
In the present study, older age and male sex were
univariate predictors of ESA resistance. Our results
confirm previous findings by Panichi and colleagues
[7] which showed that patients who belonged to the
highest ERI group were older and predominantly male [7].
Similarly, in an observational study of 1710 patients, ESA
resistance was associated with older age, but in contrast toour findings, female sex was a risk factor for ESA resistance
in this study [8]. Age and sex however are unmodifiable risk
factors. Thus, the identification of potentially modifiable
factors is of particular interest.
Several clinical studies have demonstrated that lower
albumin levels, decreased BMI as well as increased CRP
level are associated with ESA resistance in HD patients
[7,8,15,16]. The joint occurrence of malnutrition and
inflammation in HD patients is consistent with protein
energy wasting [17]. Moreover, nearly one-third of all HD
patients have mild to moderate wasting [17] and wasting is
associated with sudden cardiac death in these patients [18].
In the current study, lower albumin level and a decreased
BMI as well as higher CRP levels independently predicted
ESA resistance. As a consequence, strategies to improve
nutritional status and to lower the burden of inflammation
are likely to play an important role in order to avoid ESA
resistance as well as to prevent cardiovascular events in
these patients.
It is widely accepted that iron deficiency in HD patients
is a strong risk factor for the development of ESA-
resistance [4,19], which is consistent with our findings.
The investigators of the “European Survey on Anemia
Management” (ESAM) study found inadequate iron stores
in more than fifty percent of all patients treated with ESAs
[20]. Moreover, in a study by DeVita and colleagues, lower
doses of ESAs were required to reach target Hb levels, if
patients had higher-than-average ferritin levels [21].
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was treatment with an ACEI. This is consistent with
findings in 1513 patients from a post hoc analysis of
the RENAAL study [22]. Mohanram and colleagues
showed that losartan (ARB) treatment was associated
with a significant decrease in hemoglobin level [22].
ACEI and ARBs reduce levels of the peptide hormone
angiotensin II. Angiotensin II, besides its more widely
known effects on the cardiovascular system, also acts as a
growth-factor for the maturation of erythrocytes within the
bone marrow. Thus, inhibition of this growth-factor by
ACEI and ARBs negatively affects erythropoiesis. On the
other hand, in a cross-sectional study in 515 patients by
Saudan and colleagues the authors could not demonstrate
that the use of ACEI was associated with ESA resistance
[23]. However, most clinicians would argue that the posi-
tive effects of ACEI or ARBs on the cardiovascular system
preponderate any negative effects on erythropoiesis.
In our study, higher potassium levels were associated
with resistance to ESAs. Patients in whom it is difficult
to maintain potassium levels within the physiological
range are often inadequately dialysed. This group of
patients are frequently found to suffer from malnutrition
(e.g. low BMI) and an increased inflammatory state, which
are also, associated with ESA resistance. Furthermore, in
4D we found that the use of ACEI is associated with higher
potassium levels. Therefore, the link between higher
potassium levels and ESA resistance might be confounded
by a higher use of ACEI’s.
The best accuracy in predicting ESA resistance was
reached by adding specific non-routinely used biomarkers
to the analysis. However, the improvement in risk discrim-
ination was small. These biomarkers are expensive and not
routinely measured. In this context, we want to point out
that ESA resistance in diabetic HD patients could be well
predicted with similar accuracy by including easily obtain-
able clinical parameters and routinely assessed laboratory
variables. We clearly demonstrated that patients could be
classified according to risk of ESA-resistance with routinely
used parameters.
Several limitations are apparent in the present study.
It was a post-hoc analysis within a selected cohort of
dialysis patients with type 2 diabetes mellitus. Therefore,
the results may not be generalizable to other patient
populations, and future studies need to validate our
findings in separate cohorts. Second, further parameters
that may be of additional interest in improving the risk
prediction of ESA resistance such as parameters of
oxidative stress and hepcidin were not available. Third,
calculating ERI from single ESA and hemoglobin value
does not account for the dynamics of the erythropoiesis
process. The strengths of this study include the large
sample size and little amount of missing values only in
a comprehensive and standardized data assessment.Conclusions
We provide a prognostic model for ESA resistance based
on easily obtainable clinical parameters and routine
laboratory markers, which allows accurate identification
of diabetic HD patients at risk of ESA resistance. Specific
biomarkers did not meaningfully further improve the risk
prediction of ESA resistance. We suggest that routinely
obtained data can be used in clinical practice to stratify
patients according to the risk of ESA resistance, which
may help to assign appropriate treatment strategies.
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